Compare MSTR & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSTR | RMD |
|---|---|---|
| Founded | 1989 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2B | 33.6B |
| IPO Year | 1998 | 1996 |
| Metric | MSTR | RMD |
|---|---|---|
| Price | $142.75 | $245.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | $239.27 | ★ $251.99 |
| AVG Volume (30 Days) | ★ 15.5M | 828.7K |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.10% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | N/A | ★ 10.43 |
| Revenue | $463,456,000.00 | ★ $2,957,013,000.00 |
| Revenue This Year | $5.13 | $2.59 |
| Revenue Next Year | $2.22 | $6.92 |
| P/E Ratio | ★ N/A | $22.96 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $81.81 | $180.27 |
| 52 Week High | $299.68 | $277.67 |
| Indicator | MSTR | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 66.12 |
| Support Level | $120.08 | $217.41 |
| Resistance Level | $145.75 | $242.40 |
| Average True Range (ATR) | 7.73 | 4.70 |
| MACD | -3.79 | 1.79 |
| Stochastic Oscillator | 9.39 | 87.28 |
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software. It has one reportable operating segment: the Software Business, which is engaged in the design, development, marketing, and sales of the company's enterprise analytics software platform through cloud subscriptions and licensing arrangements and related services (i.e., product support, consulting, and education). Geographically, the company operates in EMEA, U.S. and Other Regions, of which maximum revenue is derived from U.S..
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.